| 000 | 01781 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513225823.0 | ||
| 264 | 0 | _c20010222 | |
| 008 | 200102s 0 0 eng d | ||
| 022 | _a0028-1298 | ||
| 024 | 7 |
_a10.1007/s002100000300 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWaldmeier, P C | |
| 245 | 0 | 0 |
_aCGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. _h[electronic resource] |
| 260 |
_bNaunyn-Schmiedeberg's archives of pharmacology _cDec 2000 |
||
| 300 |
_a526-37 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_a1-Methyl-4-phenylpyridinium _xtoxicity |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xpharmacology |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 | _aCell Culture Techniques |
| 650 | 0 | 4 |
_aCell Death _xdrug effects |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 |
_aMesencephalon _xcytology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aMonoamine Oxidase _xmetabolism |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aNeurons _xdrug effects |
| 650 | 0 | 4 |
_aOxepins _xpharmacology |
| 650 | 0 | 4 | _aOxidopamine |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aSelegiline _xpharmacology |
| 650 | 0 | 4 |
_aSubstantia Nigra _xenzymology |
| 650 | 0 | 4 | _aTritium |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 700 | 1 | _aSpooren, W P | |
| 700 | 1 | _aHengerer, B | |
| 773 | 0 |
_tNaunyn-Schmiedeberg's archives of pharmacology _gvol. 362 _gno. 6 _gp. 526-37 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s002100000300 _zAvailable from publisher's website |
| 999 |
_c11078913 _d11078913 |
||